Gene expression of tendon markers in mesenchymal stromal cells derived from different sources

Abstract

BackgroundMultipotent mesenchymal stromal cells (MSC) can be recovered from a variety of tissues in the body. Yet, their functional properties were shown to vary depending on tissue origin. While MSC have emerged as a favoured cell type for tendon regenerative therapies, very little is known about the influence of the MSC source on their properties relevant to tendon regeneration.The aim of this study was to assess and compare the expression of tendon extracellular matrix proteins and tendon differentiation markers in MSC derived from different sources as well as in native tendon tissue. MSC isolated from equine bone marrow, adipose tissue, umbilical cord tissue, umbilical cord blood and tendon tissue were characterized and then subjected to mRNA analysis by real-time polymerase chain reaction.ResultsMSC derived from adipose tissue displayed the highest expression of collagen 1A2, collagen 3A1 and decorin compared to MSC from all other sources and native tendon tissue (p < 0.01). Tenascin-C and scleraxis expressions were highest in MSC derived from cord blood compared to MSC derived from other sources, though both tenascin-C and scleraxis were expressed at significantly lower levels in all MSC compared to native tendon tissue (p < 0.01).ConclusionsThese findings demonstrate that the MSC source impacts the cell properties relevant to tendon regeneration. Adipose derived MSC might be superior regarding their potential to positively influence tendon matrix reorganization.Electronic supplementary materialThe online version of this article (doi:10.1186/1756-0500-7-826) contains supplementary material, which is available to authorized users.

Human adipose tissue‐derived tenomodulin positive subpopulation of stem cells: A promising source of tendon progenitor cells

“…In the current study, DCN overexpression was found in both TNMD+ and unsorted hASCs. This outcome is in agreement with the fact that DCN is relatively higher in hASCs than in MSCs from other sources and in native tendon (Burk et al, ). DCN increases from 14 to 28 days in TNMD+ subpopulations cultured in basal and PDGF‐BB media ( p < 0.01 and p < 0.001 respectively).…”

Adipose tissue as mesenchymal stem cells source in equine tendinitis treatment

“…Other study using AdMSCs suspended in PC also showed increased tendon vascularization through power Doppler analysis after six weeks of therapy (CARVALHO et al, 2013a). Such increased tendon vascularization may favor tissue repair, since poor vascularization is one of the explanations for the slow tendon repair and for the formation of a biomechanically inferior MSC (GONÇALVES et al, 2013;BURK, 2014).…”

“…The AdMSCs were those with greater type I and III collagen and decorin expression. Once the improvement in the cellular matrix has been pointed as the main beneficial effect of the cellular therapy against tendinitis, the use of adipose tissue as stem cell source may result in therapeutic effect better than that of other sources, since it has greater protein expressions such as type I collagen (BURK et al, 2014).…”

Equine Models for the Investigation of Mesenchymal Stem Cell Therapies in Orthopaedic Disease

“…69 Other cell sources, such as synovial membrane-derived MSCs may provide advantages for joint-based therapies, but are not yet extensively studied in the horse. 83 Burk et al 84 investigated the gene expression of tendon markers from different MSC sources including bone marrow-derived MSCs, adipose-derived MSCs, umbilical cord tissue-derived MSCs, and MSCs from umbilical cord blood; the study concluded that adiposederived MSCs may be more appropriate for the treatment of tendon lesions as they demonstrate the highest expression of collagen 1A2, collagen 3A1, and decorin. The earlier outlined literature suggests bone marrow-derived MSCs may be more appropriate for cartilage or bone healing, and adipose-derived MSCs may be more phenotypically appropriate for tendon lesions.…”